{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:35:49Z","timestamp":1788287749989,"version":"build-2803163510"},"reference-count":204,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    The tumor suppressor gene\n                    <jats:italic>TP53<\/jats:italic>\n                    produces multiple p53 protein isoforms through alternative promoter usage, messenger RNA splicing, and alternative translation initiation. These isoforms can differentially shape canonical p53 outputs, including cell-cycle arrest, senescence, apoptosis, and DNA-damage responses, and are increasingly recognized as context-dependent regulators of tumor progression and treatment response. However, their roles in hematological malignancies remain incompletely characterized. This review summarizes the structure, biogenesis, and functional consequences of p53 isoforms and integrates available evidence on their expression across acute leukemias, multiple myeloma, chronic lymphocytic leukemia, and selected non-Hodgkin lymphomas. We highlight reported differences between diagnostic and relapse specimens, associations with cytogenetic risk categories, and interactions with TP53 mutation backgrounds. Available data suggest that N-terminally truncated isoforms (\u039440p53, \u0394133p53\/\u0394160p53) and C-terminally spliced variants (p53\u03b2\/\u03b3) can modulate tetramer composition and downstream transcriptional programs, thereby influencing apoptosis, senescence, and DNA repair. However, the clinical significance of these patterns in hematological malignancies remains incompletely defined because the evidence is derived from relatively small and methodologically heterogeneous studies. More standardized assays and prospective validation in larger, clinically annotated cohorts are needed before p53 isoform profiling can be incorporated into routine risk stratification or therapeutic decision-making. We also discuss methodological advances and limitations in isoform detection at transcript and protein levels, including isoform-specific quantitative reverse-transcription polymerase chain reaction, antibody panels, capillary nanoimmunoassays, and targeted liquid chromatography\u2013tandem mass spectrometry. Comprehensive profiling of p53 isoforms may eventually help refine biological classification and risk assessment, but its clinical utility will depend on assay standardization and prospective validation.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1854189","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:29:19Z","timestamp":1780374559000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Biology of p53 protein isoforms and their significance in hematological malignancies"],"prefix":"10.3389","volume":"16","author":[{"given":"Anna Maria","family":"Janik","sequence":"first","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine of Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Tracz-Gaszewska","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Misiewicz-Krzemi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Jamroziak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine of Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hern\u00e1ndez Borrero","year":"2021","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3892\/ol.2018.8627","article-title":"TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer","volume":"16","author":"Huszno","year":"2018","journal-title":"Oncol Lett"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.6.5.1379-1385.1986","article-title":"Characterization of the human p53 gene","volume":"6","author":"Lamb","year":"1986","journal-title":"Mol Cell Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B7","article-title":"TP53 mutations and hematological Malignancies","volume":"59","author":"Hirabayashi","year":"2018","journal-title":"Rinsho Ketsueki"},{"key":"B8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/joim.20106","article-title":"The TP53 tumor suppressor gene: From molecular biology to clinical investigations","volume":"298","author":"Baliakas","year":"2025","journal-title":"J Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.tig.2022.02.010","article-title":"The p53 network: cellular and systemic DNA damage responses in cancer and aging","volume":"38","author":"Vaddavalli","year":"2022","journal-title":"Trends Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12030724","article-title":"TP53 expression and mutational analysis in hematological Malignancy in jeddah, Saudi Arabia","volume":"12","author":"Alkhatabi","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029691","article-title":"A clinical guide to TP53 mutations in myeloid neoplasms","volume":"146","author":"Urrutia","year":"2025","journal-title":"Blood"},{"key":"B13","volume-title":"Isoform p53 protein\u2019s major role in the pathophysiology of Malignant hematologic diseases","author":"Udristioiu","year":"2024"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1182\/blood-2025-4013","article-title":"Examining TP53-mutated plasma cell disorders across the disease spectrum using broad next generation sequencing","volume":"146","author":"Ezell","year":"2025","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.7.1500.1500","article-title":"Mutation of the p53 gene in human acute myelogenous leukemia","volume":"77","author":"Slingerland","year":"1991","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.7.1652.1652","article-title":"P53 gene mutations in acute myeloid leukemia with 17p monosomy","volume":"78","author":"Fenaux","year":"1991","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07046.x","article-title":"Mutated and non-mutated TP53 as targets in the treatment of leukaemia","volume":"141","author":"Nahi","year":"2008","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.59","article-title":"TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution","volume":"5","author":"Hou","year":"2015","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-419622","article-title":"A novel hierarchical prognostic model of AML solely based on molecular mutations","volume":"120","author":"Grossmann","year":"2012","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1438","article-title":"TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus","volume":"94","author":"Maggio","year":"2001","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0356-z","article-title":"Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis","volume":"33","author":"Liu","year":"2020","journal-title":"Mod Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03300-8","article-title":"Deletion of 17p in cancers: Guilt by (p53) association","volume":"44","author":"van Kampen","year":"2025","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/gcc.22692","article-title":"The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia","volume":"58","author":"Yuan","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.5.1.127-132.1985","article-title":"Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule","volume":"5","author":"Wolf","year":"1985","journal-title":"Mol Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1984.tb02287.x","article-title":"Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene","volume":"3","author":"Matlashewski","year":"1984","journal-title":"EMBO J"},{"key":"B28","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.3390\/ijms20246257","article-title":"The emerging landscape of p53 isoforms in physiology, cancer and degenerative diseases","volume":"20","author":"Anbarasan","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1186\/s12885-018-4591-3","article-title":"High expression of the p53 isoform \u03b3 is associated with reduced progression-free survival in uterine serous carcinoma","volume":"18","author":"Bischof","year":"2018","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/onc.2009.482","article-title":"Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer","volume":"29","author":"Hofstetter","year":"2010","journal-title":"Oncogene"},{"key":"B31","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/bcr2811","article-title":"p53 mutant breast cancer patients expressing p53\u03b3 have as good a prognosis as wild-type p53 breast cancer patients","volume":"13","author":"Bourdon","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"188882","DOI":"10.1016\/j.bbcan.2023.188882","article-title":"The role of truncated p53 isoforms in the DNA damage response","volume":"1878","author":"Steffens Reinhardt","year":"2023","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010065","article-title":"p53 family in resistance to targeted therapy of melanoma","volume":"24","author":"Vla\u0161ic","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41419-022-05349-9","article-title":"Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damage","volume":"13","author":"Steffens Reinhardt","year":"2022","journal-title":"Cell Death Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210078","article-title":"p53 dysregulation in breast cancer: insights on mutations in the TP53 network and p53 isoform expression","volume":"24","author":"Steffens Reinhardt","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.169","article-title":"How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ"},{"key":"B37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tibs.2024.10.009","article-title":"How does p53 work? Regulation by the intrinsically disordered domains","volume":"50","author":"Dyson","year":"2025","journal-title":"Trends Biochem Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.77.060806.091238","article-title":"Structural biology of the tumor suppressor p53","volume":"77","author":"Joerger","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1471-2164-10-s1-s7","article-title":"Unfoldomics of human diseases: linking protein intrinsic disorder with diseases","author":"Uversky","year":"2009","journal-title":"BMC Genomics"},{"key":"B40","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.3390\/ijms17111874","article-title":"p53 proteoforms and intrinsic disorder: an illustration of the protein structure\u2013function continuum concept","volume":"17","author":"Uversky","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.05.015","article-title":"Structural basis of DNA recognition by p53 tetramers","volume":"22","author":"Kitayner","year":"2006","journal-title":"Mol Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30331","article-title":"A comprehensive study of p53 protein","volume":"123","author":"Patil","year":"2022","journal-title":"J Cell Biochem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2017.03.030","article-title":"Mutant p53 in cancer: accumulation, gain-of-function, and therapy","volume":"429","author":"Yue","year":"2017","journal-title":"J Mol Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/387299a0","article-title":"Regulation of p53 stability by Mdm2","volume":"387","author":"Kubbutat","year":"1997","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3711","article-title":"Unravelling mechanisms of p53-mediated tumour suppression","volume":"14","author":"Bieging","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203015","article-title":"Regulation of p53 in response to DNA damage","volume":"18","author":"Lakin","year":"1999","journal-title":"Oncogene"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.4283","article-title":"Surf the post-translational modification network of p53 regulation","volume":"8","author":"Gu","year":"2012","journal-title":"Int J Biol Sci"},{"key":"B49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1074\/mcp.M113.030254","article-title":"Extensive post-translational modification of active and inactivated forms of endogenous p53","volume":"13","author":"De Hart","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41392-020-0196-9","article-title":"Regulating tumor suppressor genes: post-translational modifications","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.cell.2008.05.020","article-title":"SnapShot: p53 posttranslational modifications","volume":"133","author":"Kruse","year":"2008","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2019.1563484","article-title":"What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer","volume":"19","author":"Hayman","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"key":"B53","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2021.06.013","article-title":"DNA damage and oxidant stress activate p53 through differential upstream signaling pathways","volume":"172","author":"Shi","year":"2021","journal-title":"Free Radical Biol Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/sj.neo.7900073","article-title":"Dial 9-1\u20131 for p53: mechanisms of p53 activation by cellular stress","volume":"2","author":"Ljungman","year":"2000","journal-title":"Neoplasia"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/13510002.2017.1416773","article-title":"A systematic review of p53 regulation of oxidative stress in skeletal muscle","volume":"23","author":"Beyfuss","year":"2018","journal-title":"Redox Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202153085","article-title":"Adaptive homeostasis and the p53 isoform network","volume":"22","author":"Mehta","year":"2021","journal-title":"EMBO Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/ng0593-42","article-title":"Gain of function mutations in p53","volume":"4","author":"Dittmer","year":"1993","journal-title":"Nat Genet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.266","article-title":"p53 isoforms gain functions","volume":"29","author":"Olivares-Illana","year":"2010","journal-title":"Oncogene"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-018-0115-6","article-title":"Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1","volume":"25","author":"Fang","year":"2018","journal-title":"Cell Death Differ"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat Cell Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"10.3892\/ijmm.2024.5448","DOI":"10.3892\/ijmm.2024.5448","article-title":"TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)","volume":"55","author":"Tornesello","year":"2025","journal-title":"Int J Mol Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death Differ"},{"key":"B66","doi-asserted-by":"publisher","first-page":"10.3390\/ijms232113287","DOI":"10.3390\/ijms232113287","article-title":"Gain of function (GOF) mutant p53 in cancer-current therapeutic approaches","volume":"23","author":"Roszkowska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/0008-5472.can-23-1490","article-title":"Gain-of-function p53 mutation acts as a genetic switch for TGF\u03b2 Signaling\u2013induced epithelial-to-mesenchymal transition in intestinal tumors","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.607670","article-title":"Mutant p53 gain-of-function: role in cancer development, progression, and therapeutic approaches","volume":"8","author":"Alvarado-Ortiz","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid Malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1339905","article-title":"p53 isoforms can regulate p53 transcriptional activity","volume":"19","author":"Bourdon","year":"2005","journal-title":"Genes Dev"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26507","article-title":"Expression of p53 protein isoforms predicts survival in patients with multiple myeloma","volume":"97","author":"Rojas","year":"2022","journal-title":"Am J Hematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1177\/1947601911408893","article-title":"p53 isoforms: an intracellular microprocessor","volume":"2","author":"Khoury","year":"2011","journal-title":"Genes Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"10.1101\/cshperspect.a026039","DOI":"10.1101\/cshperspect.a026039","article-title":"p53 isoforms: key regulators of the cell fate decision","volume":"6","author":"Joruiz","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41419-024-06783-7","article-title":"Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance","volume":"15","author":"Guo","year":"2024","journal-title":"Cell Death Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000927","article-title":"The isoforms of the p53 protein","volume":"2","author":"Khoury","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2010.10.005","article-title":"\u0394160p53 is a novel N-terminal p53 isoform encoded by \u0394133p53 transcript","volume":"584","author":"Marcel","year":"2010","journal-title":"FEBS Lett"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.7400623","article-title":"Two internal ribosome entry sites mediate the translation of p53 isoforms","volume":"7","author":"Ray","year":"2006","journal-title":"EMBO Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"10.3390\/cancers10090288","DOI":"10.3390\/cancers10090288","article-title":"p53 isoforms and their implications in cancer","volume":"10","author":"Vieler","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2011.120","article-title":"Biological functions of p53 isoforms through evolution: lessons from animal and cellular models","volume":"18","author":"Marcel","year":"2011","journal-title":"Cell Death Differ"},{"key":"B81","doi-asserted-by":"publisher","first-page":"10.1101\/cshperspect.a026047","DOI":"10.1101\/cshperspect.a026047","article-title":"The transactivation domains of the p53 protein","volume":"7","author":"Raj","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4161\/23723548.2014.969136","article-title":"p53 isoforms change p53 paradigm","volume":"1","author":"Bourdon","year":"2014","journal-title":"Mol Cell Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"10.3390\/cancers14133145","DOI":"10.3390\/cancers14133145","article-title":"p53 isoforms as cancer biomarkers and therapeutic targets","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.molcel.2010.01.041","article-title":"Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53\/47","volume":"38","author":"Bourougaa","year":"2010","journal-title":"Mol Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.190736","article-title":"\u039440p53\u03b1 suppresses tumor cell proliferation and induces cellular senescence in hepatocellular carcinoma cells","volume":"130","author":"Ota","year":"2017","journal-title":"J Cell Sci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1928","article-title":"p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence","volume":"11","author":"Fujita","year":"2009","journal-title":"Nat Cell Biol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12060","article-title":"Oxidative stress activates a specific p53 transcriptional response that regulates cellular senescence and aging","volume":"12","author":"Gambino","year":"2013","journal-title":"Aging Cell"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.48","article-title":"\u0394133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells","volume":"24","author":"Horikawa","year":"2017","journal-title":"Cell Death Differ"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/jci70355","article-title":"p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes","volume":"123","author":"Mondal","year":"2013","journal-title":"J Clin Invest"},{"key":"B90","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/ott.s53876","article-title":"Uncovering the role of p53 splice variants in human Malignancy: a clinical perspective","volume":"7","author":"Surget","year":"2013","journal-title":"Onco Targets Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00636","article-title":"Targeting the bcl-2 family in B cell lymphoma","volume":"8","author":"Adams","year":"2018","journal-title":"Front Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5324.370","article-title":"Inhibition of Bax channel-forming activity by Bcl-2","volume":"277","author":"Antonsson","year":"1997","journal-title":"Science"},{"key":"B93","article-title":"Bcl-XL protects cancer cells from p53-mediated apoptosis","volume":"11","author":"Schott","year":"1995","journal-title":"Oncogene"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2010.91","article-title":"p53 directly transactivates \u0394133p53\u03b1, regulating cell fate outcome in response to DNA damage","volume":"18","author":"Aoubala","year":"2011","journal-title":"Cell Death Differ"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003246","article-title":"p53 protein isoforms: key regulators in the front line of pathogen infections","volume":"9","author":"Terrier","year":"2013","journal-title":"PloS Pathog"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1761609","article-title":"p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish","volume":"23","author":"Chen","year":"2009","journal-title":"Genes Dev"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172125","article-title":"The p53 isoform delta133p53\u00df regulates cancer cell apoptosis in a RhoB-dependent manner","volume":"12","author":"Arsic","year":"2017","journal-title":"PloS One"},{"key":"B98","doi-asserted-by":"publisher","first-page":"10.1073\/pnas.2103319118","DOI":"10.1073\/pnas.2103319118","article-title":"\u039440p53 isoform up-regulates netrin-1\/UNC5B expression and potentiates netrin-1 pro-oncogenic activity","volume":"118","author":"Sun","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/ncb801","article-title":"p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products","volume":"4","author":"Yin","year":"2002","journal-title":"Nat Cell Biol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/jid.2013.391","article-title":"Dominant effects of \u039440p53 on p53 function and melanoma cell fate","volume":"134","author":"Takahashi","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/science.7878469","article-title":"Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms","volume":"267","author":"Jeffrey","year":"1995","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41419-024-07213-4","article-title":"Interaction of p53 with the \u0394133p53\u03b1 and \u0394160p53\u03b1 isoforms regulates p53 conformation and transcriptional activity","volume":"15","author":"Tomas","year":"2024","journal-title":"Cell Death Dis"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.21091","article-title":"p53 modulation of the DNA damage response","volume":"100","author":"Helton","year":"2007","journal-title":"J Cell Biochem"},{"key":"B104","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cell.2005.10.012","article-title":"Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin","volume":"123","author":"Takagi","year":"2005","journal-title":"Cell"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.08.031","article-title":"Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26","volume":"32","author":"Ofir-Rosenfeld","year":"2008","journal-title":"Mol Cell"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1968910","article-title":"5\u2032\u20133\u2032-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage","volume":"24","author":"Chen","year":"2010","journal-title":"Genes Dev"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.669041","article-title":"DNA double-strand breaks: A double-edged sword for trypanosomatids","volume":"9","author":"da Silva","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.b1900167","article-title":"p53 and its isoforms in DNA double-stranded break repair","volume":"20","author":"Zhang","year":"2019","journal-title":"J Zhejiang Univ-Sci B"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2015.1033587","article-title":"\u0394113p53\/\u0394133p53 converts P53 from a repressor to a promoter of DNA double-stand break repair","volume":"3","author":"Gong","year":"2016","journal-title":"Mol Cell Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2015.22","article-title":"p53 isoform \u0394113p53\/\u0394133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage","volume":"25","author":"Gong","year":"2015","journal-title":"Cell Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/srep37281","article-title":"p53 isoform \u0394133p53 promotes efficiency of induced pluripotent stem cells and ensures genomic integrity during reprogramming","volume":"6","author":"Gong","year":"2016","journal-title":"Sci Rep"},{"key":"B112","doi-asserted-by":"publisher","first-page":"5244","DOI":"10.1038\/s41598-019-41706-z","article-title":"Influence of p53 isoform expression on survival in high-grade serous ovarian cancers","volume":"9","author":"Bischof","year":"2019","journal-title":"Sci Rep"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1097\/igc.0b013e31823ca031","article-title":"The N-terminally truncated p53 isoform \u039440p53 influences prognosis in mucinous ovarian cancer","volume":"22","author":"Hofstetter","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgy001","article-title":"p53\u03b2: a new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median follow-up","volume":"39","author":"Zhang","year":"2018","journal-title":"Carcinogenesis"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000003993","article-title":"Role of p53 isoforms and aggregations in cancer","volume":"95","author":"Kim","year":"2016","journal-title":"Medicine"},{"key":"B116","doi-asserted-by":"publisher","first-page":"12470","DOI":"10.1038\/s41598-019-48882-y","article-title":"Expression profiles of p53\/p73, NME and GLI families in metastatic melanoma tissue and cell lines","volume":"9","author":"Ozretic","year":"2019","journal-title":"Sci Rep"},{"key":"B117","doi-asserted-by":"publisher","first-page":"10.3390\/cancers13205231","DOI":"10.3390\/cancers13205231","article-title":"Altered expression of shorter p53 family isoforms can impact melanoma aggressiveness","volume":"13","author":"Tadijan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41467-017-02408-0","article-title":"\u0394133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling","volume":"9","author":"Campbell","year":"2018","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41419-019-1861-1","article-title":"The \u0394133p53\u03b2 isoform promotes an immunosuppressive environment leading to aggressive prostate cancer","volume":"10","author":"Kazantseva","year":"2019","journal-title":"Cell Death Dis"},{"key":"B120","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/path.5111","article-title":"Elevation of the TP53 isoform \u0394133p53\u03b2 in glioblastomas: an alternative to mutant p53 in promoting tumor development","volume":"246","author":"Kazantseva","year":"2018","journal-title":"J Pathol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6162","article-title":"Increased \u0394133p53 mRNA in lung carcinoma corresponds with reduction of p21 expression","volume":"15","author":"Fragou","year":"2017","journal-title":"Mol Med Rep"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.ra119.007566","article-title":"Loss of the p53 transactivation domain results in high amyloid aggregation of the \u039440p53 isoform in endometrial carcinoma cells","volume":"294","author":"Melo Dos Santos","year":"2019","journal-title":"J Biol Chem"},{"key":"B123","doi-asserted-by":"publisher","first-page":"10.3390\/cells10040833","DOI":"10.3390\/cells10040833","article-title":"p53 protein isoform profiles in AML: Correlation with distinct differentiation stages and response to epigenetic differentiation therapy","volume":"10","author":"Haaland","year":"2021","journal-title":"Cells"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020251","article-title":"DNA-damage-induced alternative splicing of p53","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13118","article-title":"Effect of p53 and its N-terminally truncated isoform, \u039440p53, on breast cancer migration and invasion","volume":"16","author":"Zhang","year":"2022","journal-title":"Mol Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.7554\/elife.106469.2","article-title":"\u0394133p53\u03b1 and \u0394160p53\u03b1 isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation","volume":"14","author":"Zhao","year":"2025","journal-title":"Elife"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.24.8.3536-3551.2004","article-title":"How many mutant p53 molecules are needed to inactivate a tetramer","volume":"24","author":"Chan","year":"2004","journal-title":"Mol Cell Biol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"10.3390\/cancers12113422","DOI":"10.3390\/cancers12113422","article-title":"The \u0394133p53 isoforms, tuners of the p53 pathway","volume":"12","author":"Joruiz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-62703-236-0_2","article-title":"Detecting p53 isoforms at protein level","volume":"962","author":"Marcel","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-62703-236-0_1","article-title":"Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues","volume":"962","author":"Khoury","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae855","article-title":"Re-appraising the evidence for the source, regulation and function of p53-family isoforms","volume":"52","author":"L\u00f3pez","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1097\/01.pai.0000213119.81343.7b","article-title":"Real-time PCR analysis of RNA extracted from formalin-fixed and paraffin-embeded tissues: effects of the fixation on outcome reliability","volume":"15","author":"Castiglione","year":"2007","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.181628","article-title":"A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility","volume":"103","author":"Misiewicz-Krzeminska","year":"2018","journal-title":"Haematologica"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.7b02890","article-title":"Simultaneous detection of human C-terminal p53 isoforms by single template molecularly imprinted polymers (MIPs) coupled with liquid chromatography-tandem mass spectrometry (LC-MS\/MS)-based targeted proteomics","volume":"90","author":"Jiang","year":"2018","journal-title":"Anal Chem"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.7554\/elife.103537","article-title":"p53 isoforms have a high aggregation propensity, interact with chaperones and lack binding to p53 interaction partners","volume":"13","author":"Brdar","year":"2025","journal-title":"Elife"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.297","article-title":"Prognostic landscape of TP53 mutations in hematologic Malignancies","volume":"58","author":"Jang","year":"2026","journal-title":"Cancer Res Treat"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.7150\/jca.113576","article-title":"The role of P53 in immune evasion and therapeutic strategies in hematologic Malignancies","volume":"16","author":"Wen","year":"2025","journal-title":"J Cancer"},{"key":"B138","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","article-title":"What have we learned about TP53-mutated acute myeloid leukemia","volume":"14","author":"Shahzad","year":"2024","journal-title":"Blood Cancer J"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22938","article-title":"Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype","volume":"60","author":"Warnstorf","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02835-9","article-title":"Etiology of TP53 mutated complex karyotype acute myeloid leukemia","volume":"40","author":"Fedenko","year":"2026","journal-title":"Leukemia"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood.v112.11.2521.2521","article-title":"SNP array-based analysis of chromosome 17 reveals biallelic TP53 mutations due to uniparental disomy 17p in advanced MDS and AML with cooperating deletions of chromosomes 5 and 7","volume":"112","author":"Jasek","year":"2008","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.098103","article-title":"p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)","volume":"99","author":"Saft","year":"2014","journal-title":"Haematologica"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"B005","DOI":"10.1158\/1538-7445.PEDIATRIC25-B005","article-title":"Abstract B005: Evaluation of TP53 expression in pediatric b-cell acute lymphoblastic leukemia and its correlations with clinicopathological profiles","volume":"85","author":"Thondikodan","year":"2025","journal-title":"Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.2991\/chi.k.211119.001","article-title":"How I use measurable residual disease in the clinical management of adult acute lymphoblastic leukemia","volume":"3","author":"Fernando","year":"2021","journal-title":"Clin Hematol Int"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530150823","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.11.3589","article-title":"FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia","volume":"97","author":"Stirewalt","year":"2001","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.143","article-title":"Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype","volume":"22","author":"Haferlach","year":"2008","journal-title":"Leukemia"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000354","article-title":"Transplant for TP53-mutated MDS and AML: because we can or because we should","volume":"2022","author":"Versluis","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"p53 and its isoforms in cancer","volume":"97","author":"Bourdon","year":"2007","journal-title":"Br J Cancer"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-1970","article-title":"A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia","volume":"12","author":"Anensen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.348","article-title":"Correlation analysis of p53 protein isoforms with NPM1\/FLT3 mutations and therapy response in acute myeloid leukemia","volume":"31","author":"\u00c5nensen","year":"2012","journal-title":"Oncogene"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-558833","article-title":"TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis","volume":"124","author":"Stengel","year":"2014","journal-title":"Blood"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.076786","article-title":"TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy","volume":"98","author":"Chiaretti","year":"2013","journal-title":"Haematologica"},{"key":"B164","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41408-025-01350-5","article-title":"Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults","volume":"15","author":"Harris","year":"2025","journal-title":"Blood Cancer J"},{"key":"B165","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1182\/blood.2025030498","article-title":"Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia","volume":"147","author":"Azevedo","year":"2026","journal-title":"Blood"},{"key":"B166","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12885-020-6599-8","article-title":"Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles","volume":"20","author":"Oh","year":"2020","journal-title":"BMC Cancer"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.102","article-title":"p53 haploinsufficiency and functional abnormalities in multiple myeloma","volume":"28","author":"Teoh","year":"2014","journal-title":"Leukemia"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7241","article-title":"Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature","volume":"7","author":"Lionetti","year":"2016","journal-title":"Oncotarget"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432203","article-title":"Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma","volume":"121","author":"Bergsagel","year":"2013","journal-title":"Blood"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20899","article-title":"The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy","volume":"50","author":"Boyd","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"B178","volume-title":"Chronic lymphocytic leukemia","author":"Mukkamalla","year":"2023"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2007.08.002","article-title":"Pathology of chronic lymphocytic leukemia: an update","volume":"11","author":"Inamdar","year":"2007","journal-title":"Ann Diagn Pathol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-017-0448-2","article-title":"Current treatment of chronic lymphocytic leukemia","volume":"18","author":"Jamroziak","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02267-x","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update","volume":"38","author":"Malcikova","year":"2024","journal-title":"Leukemia"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J Clin Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.25","article-title":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia","volume":"26","author":"Pospisilova","year":"2012","journal-title":"Leukemia"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.654115","article-title":"p53 protein expression in chronic lymphocytic leukemia","volume":"53","author":"Sellmann","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.62347\/lhio8294","article-title":"Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets","volume":"14","author":"Wen","year":"2024","journal-title":"Am J Cancer Res"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-129783","article-title":"Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study","volume":"112","author":"Young","year":"2008","journal-title":"Blood"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O'Shea","year":"2008","journal-title":"Blood"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-321851","article-title":"Hyperproliferation, cancer, and inflammation in mice expressing a \u0394133p53-like isoform","volume":"117","author":"Slatter","year":"2011","journal-title":"Blood"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4371","article-title":"\u0394113p53\/\u0394133p53: survival and integrity","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205664109","article-title":"Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoforms and p53 response to cellular stresses","volume":"109","author":"Wei","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2009.11.021","article-title":"Gene modulation and immunoregulatory roles of Interferon\u03b3","volume":"50","author":"Saha","year":"2010","journal-title":"Cytokine"},{"key":"B196","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukoc Biol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2015.02.001","article-title":"The p53 isoform \u0394133p53\u03b2 promotes cancer stem cell potential","volume":"4","author":"Arsic","year":"2015","journal-title":"Stem Cell Rep"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1987810","article-title":"Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs","volume":"24","author":"Ungewitter","year":"2010","journal-title":"Genes Dev"},{"key":"B200","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41419-023-06031-4","article-title":"p53 isoform expression promotes a stemness phenotype and inhibits doxorubicin sensitivity in breast cancer","volume":"14","author":"Steffens Reinhardt","year":"2023","journal-title":"Cell Death Dis"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101379","article-title":"Patient-specific responses to SMN2 splice-modifying treatments in spinal muscular atrophy fibroblasts","volume":"32","author":"Signoria","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B202","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5863\/1551-6776-24.3.194","article-title":"Nusinersen: A novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000005680","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3","article-title":"Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6\u201348 months with Duchenne muscular dystrophy amenable to exon 51 skipping","volume":"33","author":"Mercuri","year":"2023","journal-title":"Neuromuscular Disord"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1854189\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:29:22Z","timestamp":1780374562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1854189\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":204,"alternative-id":["10.3389\/fonc.2026.1854189"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1854189","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1854189"}}